Press releases

September 29, 2017

Advanced Accelerator Applications Announces European Approval of Lutetium (177Lu) Oxodotreotide (Lutathera®) for Gastroenteropancreatic Neuroendocrine (GEP-NET) Tumors

September 6, 2017

Advanced Accelerator Applications Announces First Patient in Bridging Study in Japan for Lutetium Lu 177 Dotatate (Lutathera®)

August 31, 2017

Advanced Accelerator Applications Reports 32% Sales Growth for Second Quarter 2017

August 28, 2017

Advanced Accelerator Applications Announces New Prescription Drug User Fee Act (PDUFA) date of January 26, 2018, for Lutetium Lu 177 Dotatate (Lutathera®)

July 27, 2017

Advanced Accelerator Applications Completes Resubmission of NDA for Lutetium Lu 177 Dotatate (Lutathera®) to FDA

July 21, 2017

Advanced Accelerator Applications Announces Positive CHMP Opinion Recommending Approval of Lutetium 177Lu Oxodotreotide (Lutathera®) for Gastroenteropancreatic Neuroendocrine (GEP-NET) Tumors

May 31, 2017

Advanced Accelerator Applications Reports 21% Sales Growth for First Quarter 2017

May 30, 2017

Advanced Accelerator Applications and Blue Earth Diagnostics Announce European Manufacturing and Distribution Agreements for Axumin™ (Fluciclovine (18F)) for PET Imaging of Recurrent Prostate Cancer

May 25, 2017

Advanced Accelerator Applications Appoints Christine Mikail to Board of Directors

May 18, 2017

Advanced Accelerator Applications Receives 2017 Industry Innovation Award from National Organization for Rare Disorders for NETSPOT®, a Diagnostic Drug for Neuroendocrine Tumors

March 30, 2017

Advanced Accelerator Applications Signs Strategic Supply Agreement with University of Missouri for Lutetium 177

March 23, 2017

Advanced Accelerator Applications Reports 23% Sales Growth for Fiscal 2016; Continued NETSPOT® Launch Success

March 15, 2017

Advanced Accelerator Applications to Announce Full-Year 2016 Financial Results on March 23

March 6, 2017

Advanced Accelerator Applications Announces Presentation of Quality of Life Findings from NETTER-1 Phase III Study at ENETS

March 1, 2017

Advanced Accelerator Applications Announces Addition of NETSPOT® to National Comprehensive Cancer Network® Guidelines for Evaluation of NETs

January 12, 2017

Advanced Accelerator Applications Announces New England Journal of Medicine Publication of Lutathera® NETTER-1 Phase III Results

January 9, 2017

Advanced Accelerator Applications CEO Provides Progress Report on Corporate Developments of 2016; Asserts Confidence in Ability to Address FDA Comments on Lutathera® NDA

January 4, 2017

Advanced Accelerator Applications to Present at 35th Annual J.P. Morgan Healthcare Conference

December 21, 2016

Advanced Accelerator Applications Receives Complete Response Letter from FDA for Lutathera®, an Investigational Treatment for Neuroendocrine Tumors

December 15, 2016

Advanced Accelerator Applications Announces European Commission Approval of SomaKit TOC™

December 8, 2016

Advanced Accelerator Applications Announces CMS Pass-Through Reimbursement Code for its First FDA Approved Drug NETSPOT®

November 28, 2016

Advanced Accelerator Applications Reports 15.4% Sales Growth in the Third Quarter of 2016 and Feedback from the FDA for Lutathera®, an Investigational Treatment for Neuroendocrine Tumors

November 23, 2016

Advanced Accelerator Applications to Announce Third Quarter and Nine-Month 2016 Financial Results on November 28

November 2, 2016

Advanced Accelerator Applications Announces Swiss Marketing Authorization for Two PET Diagnostic Products

October 17, 2016

Advanced Accelerator Applications Announces Positive EMA Opinion on Application for SomaKit TOC